You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA CAR-T

Showing 1 - 25 of 8,968
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • New Diagnosis Tumor
  • BCMA CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • VRD-based regimen
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • VRD
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023

Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)

Recruiting
  • Multiple Myeloma
  • Human BCMA Targeted T Cells Injection
  • Shanghai, Shanghai, China
  • +1 more
Dec 7, 2022

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)

Enrolling by invitation
  • Multiple Myeloma
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
  • London, County (optional), United Kingdom
    University College London Hospital
Sep 15, 2022

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

Multiple Myeloma Trial in Shanghai (Human Derived anti-BCMA CAR-T Injection)

Recruiting
  • Multiple Myeloma
  • Human Derived anti-BCMA CAR-T Injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Mar 27, 2022

ITP Trial in Suzhou (autologous anti-BCMA chimeric antigen receptor T cells)

Recruiting
  • ITP
  • autologous anti-BCMA chimeric antigen receptor T cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 31, 2022

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Relapsed/Refractory Multiple Myeloma Trial in New York, Nashville, Salt Lake City (CB-011)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • CB-011
  • New York, New York
  • +3 more
Feb 15, 2023

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Multiple Myeloma Trial (BCMA-TGFß CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFß CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFß CAR-T

Not yet recruiting
  • Multiple Myeloma
  • BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)
  • +3 more
  • (no location specified)
Jul 28, 2023

Multiple Myeloma Trial in Hangzhou (BCMA CAR-T cells injection)

Recruiting
  • Multiple Myeloma
  • BCMA CAR-T cells injection
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 13, 2023

POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia Trial in Hangzhou (CD19/BCMA CAR T-cells)

Recruiting
  • POEMS Syndrome
  • +3 more
  • CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 21, 2022

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

Recruiting
  • Multiple Myeloma
  • Autologous hematopoietic stem cell transplantation
  • C-CAR088
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 21, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Multiple Myeloma Trial in United States (Talquetamab)

Recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Sep 27, 2023

Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

Recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
  • BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022